Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6).

Hanno M WitteJörg RiedlAxel KünstnerAnke FähnrichJulius KetzerStephanie M J FliednerNiklas ReimerVeronica BernardNikolas von BubnoffHartmut MerzHauke BuschAlfred FellerNiklas Gebauer

Published in: Targeted oncology (2023)

Our virtual MTB approach identified potential molecularly targeted treatment options alongside targetable genomic signatures for both prDLBCL/HGBL-MYC/BCL2 and prHGBL, NOS-MYC/BCL6. These results underline the potential of MTB consultations in difficult-to-treat lymphomas early in the treatment sequence.

Keyphrases

transcription factor
mycobacterium tuberculosis
pulmonary tuberculosis
diffuse large b cell lymphoma
dna methylation
risk assessment
nitric oxide
human health
copy number
climate change
general practice